1 |
Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127.
|
2 |
Assessment of sucralfate coating by sequential scintigraphic imaging in radiation-induced esophageal lesions. Gastrointest Endosc. 1995 Feb;41(2):109-14.
|
3 |
Clinical pipeline report, company report or official report of Ohr Pharmaceutical.
|
4 |
DVC1-0101 to treat peripheral arterial disease: a Phase I/IIa open-label dose-escalation clinical trial. Mol Ther. 2013 Mar;21(3):707-14.
|
5 |
Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
|
6 |
Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
|
7 |
Expression of fibroblast growth factor-2 transcripts in the healing of acetic acid-induced gastric ulcers. APMIS. 1999 Aug;107(8):767-72.
|
8 |
US patent application no. 2010,0278,784, Methods and compositions for treating skin conditions.
|
9 |
How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
|
10 |
Brolucizumab: First Approval. Drugs. 2019 Dec;79(18):1997-2000.
|
11 |
National Cancer Institute Drug Dictionary (drug id 43234).
|
12 |
ClinicalTrials.gov (NCT03610646) Comparative Study to Evaluate the Efficacy and Safety of MYL-1701P and Eylea in Subjects With Diabetic Macular Edema. U.S. National Institutes of Health.
|
13 |
Clinical pipeline report, company report or official report of Fujifilm.
|
14 |
Clinical pipeline report, company report or official report of Kodiak Sciences.
|
15 |
Prevalence of porcine cysticercosis in Vellore, South India. Trans R Soc Trop Med Hyg. 2013 Jan;107(1):62-4.
|
16 |
MYL-1402O: A Bevacizumab Biosimilar. Target Oncol. 2022 Jan;17(1):85-88.
|
17 |
Efficacy and Safety of the Aflibercept Biosimilar SB15 in Neovascular Age-Related Macular Degeneration: A Phase 3 Randomized Clinical Trial. JAMA Ophthalmol. 2023 Jul 1;141(7):668-676.
|
18 |
Apoptogenic activity of 2alpha,3alpha-dihydroxyurs-12-ene-28-oic acid from Prunella vulgaris var. lilacina is mediated via mitochondria-dependent activation of caspase cascade regulated by Bcl-2 in human acute leukemia Jurkat T cells. J Ethnopharmacol. 2011 Jun 1;135(3):626-35.
|
|
|
|
|
|
|